While Merck & Co. Inc. continues its stepwise downsizing, the pharma is sending signals that the welcome mat is out for BD&L deals.

The pharma made good on its plan to seek alternatives for its consumer health business with last week's sale of the unit to Bayer AG for $14.2 billion.